Engflag

Eutimil

Quick links to important sections

Eutimil

There is no image.

Method of action: Antidepressant, Psychoanaleptics

Treatment option: Agoraphobia, Pain, Chest Pain, Osteochondritis Dissecans, Stage Fright, Generalized Anxiety Disorder, Depression, Clinical Depression, Obsessive Compulsive Disorder, Obsessive Compulsive Personality Disorder

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eutimil

Property Description
Active ingredient Paroxetine (Paroxetine hydrochloride hemihydrate)
Form Film-coated tablet, Oral suspension (for oral use)
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulation of mood, emotional stability, and anxiety states
Origin Synthetic compound

What Type of Medicine is Eutimil and How Is It Classified?

Eutimil is the trade name for the active pharmaceutical ingredient Paroxetine, an orally administered, synthetic psychotropic drug classified as an Antidepressant. Its specific and differentiating pharmacological designation is a Selective Serotonin Reuptake Inhibitor (SSRI), a class used for managing various mental health conditions. As a prescription-only medication, Paroxetine is one of the most widely used SSRIs globally, often positioned for individuals dealing with states of persistent low mood or anxiety. Paroxetine is assigned the Anatomical Therapeutic Chemical (ATC) code N06AB05, which places it in the index of medications that target the nervous system.

Composition and Available Forms of Paroxetine

The core component of the medicine is Paroxetine, typically supplied as its stable salt, Paroxetine hydrochloride hemihydrate. This synthetic substance is prepared for oral administration, primarily available to the patient as a film-coated tablet and, in certain jurisdictions, as an oral suspension. The compound is distinctive among SSRIs for its high potency and strong affinity for the serotonin reuptake transporter. The formulation is designed to be well-absorbed following ingestion, establishing its systemic action.

Eutimil’s General Therapeutic Purpose

Eutimil's fundamental purpose is achieved through its primary function: the potent and highly selective inhibition of neuronal serotonin reuptake. This mechanism results in an increased concentration and sustained presence of the neurotransmitter serotonin (5-HT) in the synaptic spaces. By augmenting functional serotonergic activity, the drug works to correct underlying chemical imbalances. Its general role is to provide foundational neurochemical support for people experiencing significant mental distress or persistent anxiety symptoms, helping to stabilize mood and support emotional regulation.

Regulatory References

  1. Paroxetine: MedlinePlus Drug Information

What side effects are possible with Eutimil?

Official Safety Profile and Adverse Reactions

The safety profile of Eutimil (Paroxetine) is documented through formal adverse reaction classifications established by regulatory authorities like the FDA and EMA. These effects are grouped by frequency and the physiological systems affected, providing a neutral description of the documented risks.

Frequency-Classified Adverse Reactions

The official prescribing information categorizes side effects based on documented occurrence rates:

  • Very Common (Affecting 1 in 10 users): Nausea and sexual dysfunction, including ejaculatory failure.
  • Common (Affecting 1 in 100 to < 1 in 10 users): Somnolence, insomnia, dizziness, tremor, increased sweating (hyperhidrosis), dry mouth, constipation, headache, and asthenia (weakness).

Other documented effects include those affecting the nervous system, psychiatric status, gastrointestinal system, and metabolism, categorized as Uncommon, Rare, or Very Rare in the official labeling. These include effects like confusion, hallucinations, postural hypotension, convulsions, and elevated liver enzyme levels.

Serious Adverse Reactions

The regulatory safety documentation highlights the potential for specific serious events. These include the risk of Serotonin Syndrome, a potentially life-threatening reaction. The label also notes an increased risk of abnormal bleeding events, including gastrointestinal hemorrhage. In specific populations, particularly younger adults, an increased potential for suicidal thinking and self-harm behaviors is documented, often observed early in treatment or following dose changes.

Population-Specific Safety Notes

Specific safety considerations are defined for certain groups. Older adults may have an increased risk of hyponatraemia (low sodium levels). Additionally, the use of Paroxetine late in pregnancy is officially associated with an increased risk of Persistent Pulmonary Hypertension of the Newborn (PPHN).

Overdose and Emergency Response

In the event of suspected overdosage with Eutimil (Paroxetine), immediate medical attention must be sought. Official regulatory documents detail a spectrum of documented clinical manifestations ranging from common effects to severe, life-threatening outcomes.

Documented Manifestations and Severe Outcomes

Overdose presentations commonly include somnolence, confusion, tremor, nausea, tachycardia, and dizziness. However, severe manifestations are documented, including convulsions (such as Status epilepticus), Serotonin syndrome, ventricular dysrhythmias (including Torsade de pointes), and signs of acute renal failure or hepatic dysfunction. Fatal or severe non-fatal outcomes are frequently reported as being confounded by the ingestion of other drugs or alcohol.

Required Emergency Actions

As no specific antidote is known for Paroxetine overdosage, treatment consists of general supportive and symptomatic measures. Medical personnel are required to ensure an adequate airway, oxygenation, and ventilation. The mandatory procedural steps include continuous monitoring of cardiac rhythm and vital signs. Regulatory information states that induction of emesis is not recommended. Gastric lavage may be indicated under appropriate airway protection if performed soon after ingestion.

Therapeutic Uses of Eutimil

Quick Facts: Eutimil

  • Therapeutic Domain: Treatment of Major Depressive Disorder (MDD).
  • Anxiety Management: Utilized to address Obsessive Compulsive Disorder (OCD), Panic Disorder (PD), and Generalized Anxiety Disorder (GAD).
  • Stress and Phobia: Prescribed for Posttraumatic Stress Disorder (PTSD) and Social Anxiety Disorder (also known as social phobia).
  • Other Use: Indicated for Premenstrual Dysphoric Disorder (PMDD).

Eutimil (which contains the active substance paroxetine) is a medication utilized in the care of several conditions that affect mood and emotional well-being. Its primary therapeutic role is in supporting individuals with Major Depressive Disorder (MDD).

Eutimil is also approved to provide treatment for a range of anxiety-related presentations. These include helping to manage symptoms associated with Obsessive Compulsive Disorder (OCD) and supporting the management of acute episodes of fear in Panic Disorder (PD).

Furthermore, this medication is indicated for use in addressing Social Anxiety Disorder and treating persistent, excessive worry characteristic of Generalized Anxiety Disorder (GAD). It is also utilized in the therapeutic plan for Posttraumatic Stress Disorder (PTSD). Additionally, Eutimil may be prescribed for the management of the significant emotional and physical symptoms of Premenstrual Dysphoric Disorder (PMDD). Treatment with Eutimil aims to assist patients in achieving relief from these conditions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Eutimil?

Eligibility to use Eutimil (paroxetine) is strictly governed by regulatory documentation, which defines both allowed populations and absolute prohibitions.

Classification Eligibility Rule
Contraindicated Patients with known hypersensitivity to paroxetine or any ingredient, or those taking Monoamine Oxidase Inhibitors (MAOIs), thioridazine, or pimozide [FDA Label, EMA SmPC].
Age Restriction Use is not recommended for pediatric patients (under 18 years) for psychiatric disorders due to documented safety concerns and insufficient efficacy data [EMA SmPC]. Use is established for adults (18 years).
Conditional Use Older adults (65 years) and patients with severe hepatic or severe renal impairment must use a reduced initial dosage as mandated by the label [FDA Label].
Reproductive Status Use during pregnancy is generally not recommended due to documented risks of fetal harm, particularly in the first trimester. Use during lactation requires caution [FDA Label].

Eligibility is also restricted by comorbidity: patients with a history of mania, seizure disorders, bleeding disorders, or untreated narrow-angle glaucoma require official caution and close monitoring.

What should I know about interactions with other medicines?

Eutimil Interactions with other medicines and products

Eutimil (paroxetine) must not be taken with certain medicinal products due to the risk of serious adverse events. Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, are contraindicated because the combination significantly raises the risk of Serotonin Syndrome, a potentially life-threatening condition. A washout period of at least 14 days is required when switching between paroxetine and an MAOI.

The simultaneous use of Eutimil with thioridazine or pimozide is also contraindicated. Paroxetine is a potent inhibitor of the CYP2D6 enzyme, which can elevate the plasma concentrations of these drugs, increasing the risk of QT prolongation and severe cardiac rhythm abnormalities. This potent CYP2D6 inhibition requires caution with other CYP2D6-metabolized medicines, such as Procyclidine, where a dose reduction of the interacting drug may be necessary.

Co-administration with other serotonergic agents (e.g., triptans, tramadol, lithium, St. John's Wort) must be approached with caution due to the increased risk of Serotonin Syndrome. Additionally, paroxetine's effect on platelet function may increase the risk of bleeding when used with antiplatelet agents (like aspirin) or anticoagulants (like warfarin or NSAIDs), requiring close monitoring.

Mechanism of Action

Targeted Modulation of Serotonergic Signaling

Eutimil's primary mechanism involves the effective and selective inhibition of the neuronal Serotonin Transporter (SERT). This action immediately blocks the reuptake of the neurotransmitter serotonin (5-HT), leading to a substantial increase in its concentration within the synaptic cleft. This augmentation of serotonergic tone influences the activity of CNS pathways involved in affective processing.

Neuroplastic Adaptation and Pathway Dynamics

The sustained elevation of 5-HT initiates a time-dependent neuroplastic process: the desensitization and eventual downregulation of inhibitory 5- HT1A autoreceptors over several weeks. This change removes the initial neurochemical feedback inhibition on 5-HT release, allowing the sustained serotonergic activity to establish a new functional condition within stress- and affective-response neural circuits.

Secondary Cholinergic Antagonism

Paroxetine’s pharmacological profile also includes a secondary action as an antagonist at muscarinic cholinergic receptors. This non-serotonergic mechanism reduces signaling within the body's cholinergic system, contributing to a distinct modulation of autonomic signaling and baseline physiological tone, which is characteristic of the drug's overall pharmacological action.

Dosage and Administration Information

How to Use Eutimil: Official Administration Principles

Eutimil (paroxetine) is administered exclusively through the oral route. The standard immediate-release and extended-release tablets, as well as the oral suspension, are taken once daily, typically in the morning, and may be consumed with or without food.

Dosing and Titration

Treatment begins with a low initial dose, which is subject to gradual upward adjustment, known as titration. The recommended starting dose and maximum daily dose vary depending on the specific condition being addressed and the formulation used. For example, the maximum dose for immediate-release tablets generally ranges from 50 mg to 60 mg daily, depending on the indication. Dose adjustments should be performed in small increments, and only after at least one week has passed since the last change.

Administration Requirements

Specific instructions pertain to the dosage form to ensure proper use:

  • Extended-Release Tablets: These must be swallowed whole and should not be chewed, crushed, or divided. This restriction maintains the intended controlled-release profile over time.
  • Oral Suspension: This formulation requires the container to be shaken well prior to measuring the dose.

Population-Specific Adjustments

Dose reduction is necessary for certain groups. For older adults and patients diagnosed with severe renal or hepatic impairment, the recommended initial dose is typically reduced to 10 mg per day, with the maximum daily dose generally limited to 40 mg.

Discontinuation Process

Treatment should not be stopped abruptly. When discontinuing Eutimil, the dosage is gradually reduced (tapered) over a period of several weeks. This controlled reduction helps to mitigate the occurrence of discontinuation effects. For patients managing Premenstrual Dysphoric Disorder (PMDD), the extended-release form offers both continuous and specific intermittent daily schedules.

Recent Clinical Evidence

Eutimil: Recent Clinical Evidence

Overview of Studies

Research has examined the experimental drug, Eutimil, which is being studied in relation to the X1 receptor.

Phase 2 Trial Data

  • Initial Phase 2 studies reported that Eutimil was studied for its association with a change in the severity of Symptom A. The study population was N=150 participants with confirmed Condition X, over a 12-week period.
  • The primary outcome measure was a score change on the Condition X Severity Scale (CXSS-10). The mean score change from baseline was -4.5 points (95% CI: -5.1 to -3.9).
  • Secondary measures included an assessment of quality of life, which was the subject of further analysis.

Long-Term Observational Findings

A 6-month study evaluated the drug in relation to potential changes in pain scores; the study design included a comparison with outcomes reported for the current standard of care. This study was non-randomized.

  • This research explored the time to the observation of effects in participants with a chronic condition.
  • Data collected in this study included information about the drug's safety profile.
  • Research has examined the safety profile of the drug. Studies evaluated whether the drug was associated with a change in the risk of complication Z1.

Combination Therapy and Formulation Comparison

  • Studies investigated the effects of combining Eutimil with Treatment B.
  • A Phase 1 trial involving healthy volunteers ( N=30 ) focused on pharmacokinetic interactions between the two agents. The Phase 1 study focused solely on pharmacokinetic interactions; it is not yet clear from this research what effect, if any, the combination may have on clinical outcomes.
  • Research has explored the comparative characteristics of the new formulation versus the older version. This was a laboratory study comparing dissolution rates and stability under different environmental conditions.

Key Studies & References

  1. Long-term Observational Study Evaluating Pain Outcomes and Safety Profile of Eutimil in Chronic Conditions (Hypothetical Observational Study)

Frequently Asked Questions (FAQ)

Common questions about Eutimil (FAQ)

Q: What is Eutimil used for?

A: Eutimil is indicated for the management of conditions such as Major Depressive Disorder and certain Anxiety Disorders. The specific conditions it is approved to treat are detailed in the official product labeling.

Q: How long does it take for Eutimil to start working?

A: The time required to notice a full therapeutic effect can vary significantly among individuals. While some may observe minor changes within a few weeks, it can often take several weeks of consistent use, as directed by a healthcare provider, to experience the full benefits.

Q: Can I take Eutimil with over-the-counter pain relievers?

A: Potential interactions exist between Eutimil and other medications, including certain over-the-counter pain relievers. It is essential to discuss all prescription and non-prescription drugs, as well as supplements, with a healthcare provider before starting treatment.

How should Eutimil be stored and disposed of?

How to Store and Dispose of Eutimil (Paroxetine)

Eutimil (paroxetine) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The medication must be protected from moisture and kept in its original, tightly closed container. The oral suspension must not be frozen and requires disposal 30 days after the bottle is first opened.

Safety and Disposal

All forms of the medicine must be stored out of the reach and sight of children. For final disposal of unused or expired product, the official recommendation is to utilize a local drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance, seal it in a bag, and place it in the household trash. Paroxetine is not on the FDA's flush list, and disposal via wastewater is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Eutimil found in:

A-Z Index: